Close Menu

NEW YORK (GenomeWeb) – GenMark recently announced that the last of three planned multiplex molecular diagnostic assays to detect blood stream infection pathogens has been cleared by the US Food and Drug Administration. The firm has been offering two multiplex panels — one for gram-positive bacteria and one for fungi — for about four months, but the addition of a third panel for gram-negative bacteria completes a suite for identifying pathogens in blood cultures, which is anticipated to now bring in new business.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.